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As inherited germ line mutations, such as loss of BRCA1 or AT, account for less than 5% of all
breast cancer, most cases involve acquired somatic perturbations. Cumulative lifetime exposure
to bioavailable estradiol links most known risk factors (except radiation) for breast cancer. Based
on a series of recent experimental and epidemiologic findings, we hypothesize that the multistep
process of breast carcinogenesis results from exposure to endogenous or exogenous hormones,
including phytoestrogens that directly or indirectly alter estrogen metabolism. Xenohormones are
defined as xenobiotic materials that modify hormonal production; they can work bifunctionally,
through genetic or hormonal paths, depending on the periods and extent of exposure. As for
genetic paths, xenohormones can modify DNA structure or function. As for hormonal paths, two
distinct mechanisms can influence the potential for aberrant cell growth: compounds can directly
bind with endogenous hormone or growth factor receptors affecting cell proliferation or
compounds can modify breast cell proliferation altering the formation of hormone metabolites that
influence epithelial-stromal interaction and growth regulation. Beneficial xenohormones, such as
indole-3-carbinol, genistein, and other bioflavonoids, may reduce aberrant breast cell proliferation,
and influence the rate of DNA repair or apoptosis and thereby influence the genetic or hormonal
microenvironments. Upon validation with appropriate in vitro and in vivo studies, biologic markers
of the risk for breast cancer, such as hormone metabolites, total bioavailable estradiol, and free
radical generators can enhance cancer detection and prevention. Environ Health Perspect
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Introduction
As the most common cancer among
women in modern societies, breast cancer
is a complex and important disease. The
average patient who dies with the disease
loses about two decades of life, so that
nearly 2 million women-years of life are
lost annually to breast cancer in the United
States and Europe (1). Although about
87% ofall cases survive for 5 years, nearly
halfofall women die from to breast cancer
by one decade after diagnosis (1-3).
About one-third of all cases of breast
cancer can be attributed to recognized risk
factors. Neither changes in established risk
factors nor screening practices completely
account for the persisting 1% annual
increase in the incidence of breast cancer.
Similarly, changes in risk factors or in
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screening practices do not explain geo-
graphic variations in prevalence ofthe dis-
ease (1-4). Inherited germ cell mutations
occur in about 5% ofall cases and in about
30% ofcases under 40 years ofage (3-6).
The common tie linking most of the
established risk factors, aside from these
mutations, is greater cumulative exposure
to bioavailable 17,-estradiol (E2) (4,7-11).
Bioavailable E2 is defined as a free hor-
mone not bound to steroid hormone-
binding globulin (SHBG) or weakly bound
to albumin (9-12). Women with elevated
levels ofbioavailable E2 have a 2- to 4-fold
excess risk of breast cancer (10). Bio-
available E2 can diffuse into cells and sub-
sequently be taken into the nucleus where
it can bind to the estrogen receptor (ER).
The hormone also can be converted in the
cytoplasm into other biologically active
metabolites and free radicals (4,7). In
addition, other hormones, such as andro-
gens and progestagens, can influence the
production and metabolism of E2
(4,9-12). The hormone-SHBG complex
bound to the cell surface receptor induces
cAMP-mediatedphosphorylation (12).
Medical Hypothesis
We have previously suggested that
compounds functioning as xenoestrogens
affect the rate and type ofestradiol metabo-
lites formed. Xenoestrogens may also bind
directly with the ER to modulate breast cell
proliferation and thereby influence the
development of breast cancer and other
hormonally mediated diseases (9,11,12). In
this report we expand the hypothesis to
include a more detailed consideration of
possible genetic-hormonal-environmental
interactions (3,4), including the complex
relationship among estrogens, androgens,
their antagonists, and other hormones in
breast cancer development.
Based on recent experimental and
epidemiologic findings in this laboratory
and elsewhere (4,9,11,13), we hypothesize
that prenatal, adolescent, or midlife expo-
sure to endogenous endocrine agents, xeno-
hormones, or their metabolites can have
bifunctional effects on the risk ofdeveloping
breast cancer.
We also hypothesize that some xeno-
hormonal exposures can, through redox
cycling between estrogens and their corre-
sponding quinones, yield reactive oxygen
species that can cause structural oxidative
damage to DNA and increase rates ofoxida-
tive DNA base modifications (7,8,14-16).
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Lipid oxidation products may also function
as endogenous DNA damaging-agents
(17). In addition, other types ofreactive
functions, such as methylation orphospho-
rylation, can affect key functional regions
ofDNA, induding cell cycle genes critical
for cell proliferation, development, and
growth. Exposure to xenohormones
through diet, pharmaceuticals, and envi-
ronmental chemicals can alter the
parenchymal environment, either by pro-
moting already initiated breast cells into
relatively rapid proliferation or by imped-
ing such growth, ifthe xenohormones are
antioxidants, hormone antagonists, or
antiangiogenics (18).
Figures 1 to 3 show the impact of
steroid hormones on interacting genetic
and hormonal pathways critical for breast
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Figure 1. Impact of steroid hormones on genotoxic
pathways of breast carcinogenesis. In the genotoxic
pathway, bioavailable 17p-estradiol is converted via
Cyp450-dependent hydroxylases to 16a-OHE1, 4-OHE1,
or 4-OHE2. These metabolites, by virtue of their direct
effect on DNA, cause genotoxic DNA damage. This
damagealterstheexpression ofcell cycle related genes,
oncogenes, and tumor suppressor genes leading to
aberrant proliferation and breast cancerdevelopment.
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Figure 2. Impact of steroid hormones on hormonal
pathways of breast carcinogenesis. In the hormonal
pathway, the E2 metabolites having estrogenic proper-
ties (16a-OHE1, 4-OHE1, or 4-OHE2) or antiestrogenic
properties (2-OHE1, 2-OHE2, and 2-MeOHEj) exert their
growth modulatory effects indirectly via receptor-medi-
ated mechanisms. These alterations lead to modula-
tion of aberrant proliferation and of breast cancer
development.
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Figure 3. Bifunctional pathways to breast cancer. In
the bifunctional pathway, the E2 metabolites affect cell
proliferation and breast cancer development either
directly via receptor-independent mechanisms involving
structural/functional alterations in DNA, or indirectly
via receptor-dependent mechanisms involving pheno-
typic growth regulation. Both mechanisms eventually
upregulate aberrant proliferation and development of
breast cancer.
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antioxidant formation, or by otherwise
enhancing the ability ofthe cell to override
signals that would produce uncontrolled
growth. Recently several researchers
reported that the average age ofonset ofthe
disease has fallen in carriers of BRC41 as
well (5,6). Thus exogenous factors appear
to affect the timing and expression ofbreast
cancer in those with predisposing germ cell
mutations. Under this hypothesis, xenohor-
monal-genetic interactions could account
forvariations in gene expression.
Hormone Metabolism
and Breast Cancer
Many steroid hormones are involved in the
development of the human breast. The
mammotropic steroids estrogen and prog-
esterone are as crucial for breast-cell prolif-
eration as the lactogenic hormones
prolactin and glucocorticoids are for cytod-
ifferentiation (3,4,11,13,19). Thus hor-
mone-mediated alterations in proliferative
and cytodifferentiative status may regulate
carcinogenesis. Receptors for most ofthe
steroid hormones are reported to be upreg-
ulated in clinical breast cancer (20-22).
The complex interacting influences of
steroid hormones on breast carcinogenesis,
however, remain to be elucidated.
Although a role ofandrogens in breast
cancer remains to be unequivocally estab-
lished, researchers have long observed that
the higher the cumulative levels of
bioavailable E2, the greater the endogenous
rate ofbreast-cell division andthe cumulative
risk ofbreast cancer (4,11). Endogenous E2
and most natural plant estrogens (phyto-
estrogens) are metabolized and excreted
relatively rapidly and readily bind to SHBG,
whereas mostxenoestrogens do not appear to
have this binding capacity (11,12,23-25).
Moreover, the half-life ofsome lipophilic
xenoestrogens, such as the organochlorine
pesticides, can extend over several decades,
in contrast to most natural estrogens, which
are metabolized completely within several
minutes orhours.
We and others (9-13,23-24) have
suggested that two competing, mutually
exclusive enzymatic pathways can alter the
production of bioavailable estradiol.
Pathway 1 inserts a hydroxyl (-OH) func-
tion at the C2- position and yields the
catechol estrogen 2-hydroxyestrone (2-
OHE1), a weakly estrogenic metabolite.
Pathway 2 adds an OH at the C16a posi-
tion and yields 16a-hydroxyestrone (16a-
OHE1); this creates afully potent estrogenic
metabolite that can covalently bind to the
ER (Figure4).
Our studies on murine mammary
epithelial cell cultures have shown that ini-
tiators ofrodent mammary carcinogenesis
(chemical carcinogens, oncogenes, and
transforming retroviruses) upregulate path-
way 2 at the expense of pathway 1
(3,26-29). Exposure ofimmortalized but
nontumorigenic murine mammary epithe-
lial cells to 16a-OHE1 results in genotoxic
DNA damage and increased cellular prolif-
eration in anchorage dependent and
anchorage independent growth conditions
in a manner similar to that induced by
treatment with the complete carcinogen
7,12-dimethylbenz[a]anthracene (DMBA)
(25). In contrast, 2-OHE1 lacks these
activities and downregulates the effects of
DMBA (28-29). In carcinogen initiated
and in tumor-derived cells, 16a-OHE1
enhances, while 2-OHE1 inhibits, the
expression of transformed phenotype
(11,13,24,26). Similar changes have been
reported in the human mammary explant
and cell culture models (13,28). It is there-
fore conceivable that the cellular metabo-
lism of E2 is altered during rodent and
human mammary carcinogenesis and that
individual metabolites may exert distinct
biological effects during initiation or pro-
motion of carcinogenesis. Furthermore,
experiments on laboratory models ofmam-
mary carcinogenesis have shown that the
naturally occurring phytochemical indole-
3-carbinol and omega-3 polyunsaturated
fatty acid prevent carcinogenic transforma-
tion, largely due to enhancement of the
C2-hydroxylation of E2 that leads to
increased formation of antiproliferative
2-OHE1 (11,24,31).
The ratio of 16a-hydroxyestrone to
2-hydroxyestrone has been found to be ele-
vated in women and experimental animals
with high rates of mammary tumors
(13,30,32). In human mammary carci-
noma cell cultures, some organochlorine
pesticides activate the type ofCyp450 that
is responsible for 16a-hydroxyestrone for-
mation and produce elevated metabolite
ratios, comparable to that induced by the
known rodent carcinogen DMBA (24).
A number of studies indicate that
16a-hydroxylation of E2 plays a bifunc-
tional role in the development of breast
cancer. The estrogen receptor as a recog-
nized transcription factor may be central to
the process by which estrogen metabolites
induce genomic changes. This process
indudes the ability ofER to bind to appro-
priate DNA response elements, enhance
transcriptional activation, and initiate a
cascade of events involving expression of
several estrogen-responsive genes such as
pS2, c-fos, c-jun, and c-myc, which code for
positive growth regulatory nuclear proteins
(33). Other metabolites ofestradiol exhibit
reversible binding to ER. Work from this
laboratory indicates that 16a-OHE1 has
the unique capacity to bind covalently and
irreversiblywith the ER (13,34).
Natural variations in the levels of
endogenous estrogen metabolism leading to
the formation ofmetabolites with distinc-
tive biological activity may explain some
reported ethnic and geographic variations in
breast cancer. Asian women, who have
much lower rates ofbreast cancer and breast
secretions, generally have higher levels of
2-OHE1 and low levels of 16a-OHE1
(9,11,23,35). Diets rich in vegetables, fruits,
and grain products could represent an addi-
tional source ofphytoestrogens capable of
modifying breast carcinogenesis.
The relative importance of various
metabolites ofE2 in the process ofcarcino-
genesis has been addressed in several
models. The catechol estrogens 2-OHE1, 4-
OHE1, 2-OHE2, and 4-OHE2 have docu-
mented pleiotropic effects on organ-site
carcinogenesis. For example, the catechol
estrogens 4-OHE2 and 4-OHE1 are
reported to function as genotoxic agents in
the hamster kidney model, in part due to
their ability to induce oxidative DNA dam-
age via free radical generation (7,8,36-38).
Microsomes from human fibroadenoma
and adenocarcinoma exhibit higher levels of
4-OHE2 than of 2-OHE2 compared to
normal breast tissue (7,8). In vivo and
in vitro studies from our laboratory have
shown that during mammarycarcinogenesis,
formation of2-OHE1 is decreasedwhile that
of 16a-OHE1 is increased, and agents that
increase 2-OHE1 inhibit carcinogenesis
(26,28,29,39). Thus positive regulation of
growth by 16a-OHE1, 4-OHE1, and 4-
OHE2 and negative regulation by 2-
OHE1 and 2-OHE2 may be consistent
with the estrogenic or antiestrogenic prop-
erties ofspecific metabolites ofE2. Despite
the pleiotropic effects of E2 metabolites,
the general consensus is that bioavailable
E2 has an important role in the risk for
breast cancer (4,9,11,23,35). The role of
other hormones in breast carcinogenesis,
however, remains to be elucidated.
Structural And Functional
Damage To DNA
Distinct endogenous processes can alter
the structure or function ofDNA, includ-
ing oxidation, methylation, deamination,
phosphorylation, and depurination.
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Oncogenes have been considered molecular
targets whose gain offunction is associated
with cancer. An array oftumor suppressor
genes such as BRCA1, Rb, DCC, p53, and
ataxia telangiectasia, mutated (ATM) allow
cancer to proceed undisturbed when their
editing and review functions are lost
through phosphorylation or other changes
(5,6,26,33). In addition, growth factors and
hormone receptors can also independently
stimulate cell proliferation or activate hor-
mone-responsive genes without causing
structural damage to DNA (3,4,17,26,33).
Metabolism of oxygen ipvolving a
chain ofone-electron reductions and the
formation of DNA-reactive free radicals
plays a pivotal role in the cause ofextensive
structural or functional damage to DNA.
One-electron oxidation of the catechol
estrogen 4-OHE2 leads to the formation of
a semiquinone that is a reactive species.
Semiquinones can be further oxidized to
quinones. Alternatively, semiquinones can
react to give superoxide ions, which in turn
yield H202. The hydrogen peroxide thus
formed then yields the reactive -OH
moiety. Free radicals produced from
semiquinones can directly damage the
phosphodiester bonds or alter the DNA
nucleotide base sequence, thereby impair-
ing normal transcriptional processes
(7,8,14-16,36-38). Free-radical induced
damage may also cause the loss of tumor
suppressor gene function, reduce natural
killer cells, impair enzymatic detoxification
processes, or altergrowth factor synthesis.
Several investigations demonstrate that
hydroxyl (-OH) radicals and oxidative
metabolites ofaromatic hydrocarbons can
irreparably and specifically modify the
structure ofDNA, leading to mutagenesis
and carcinogenesis (7,8,14-16,40).
Distinctive types of-OH-induced modifi-
cations in DNA bases have been detected
in women with breast cancer and in those
at risk for the disease, compared to con-
trols, who have undergone reduction
mammoplasty. DNA from mammoplasty
patients had relatively higher proportions
of ring opening product of adenine,
4,6-diamino-5-formamidopyrimidine
(Fapy-A), whereas cancer patients had
markedly lower levels ofFapy-A and higher
levels of8-hydroxyquanine (16). Ithas been
suggested that the relevance ofoxidative
DNA damage in breast cancer reduction is
predominantly due to H202 generation.
H202 can cross the nuclear membrane,
where it is converted bythe iron- or copper-
catalyzed Fenton reaction to the free radical
*OH. Some xenoestrogens and estrogen
metabolites may promote the production
of free radicals by redox cycling of H202
mediated by cytochrome P450 oxidase
and reductase, leading to production of
DNA-damaging reactive oxygen species.
Another critical pathway to breast
cancer can arise from agents that affect
genes for regulatory proteins, such as phos-
phatidylinositol-3-kinases (PI-3-kinases).
These proteins are essential for detecting
DNA damage. PI-3-kinase may function
by halting improper cell growth and divi-
sion until damage is repaired. Persons who
have inherited ATMand are lacking this
key regulatory gene are unable to recover
from radiation and possibly other DNA-
damaging exposures. Consequently, they
accumulate harmful mutations much more
readily than healthy persons. Some experi-
mental and epidemiologic evidence sug-
gests that women who inherit a single
defective copy ofATMare at increased risk
ofbreast cancer compared with those with
normal AT. Experimental cell culture
studies reveal that cells containing a single
faulty copy ofATMincur a higher death
ratefollowing radiation exposure.
Discussion
Development ofcancer is the consequence
ofcomplex and subtle interactions between
the environment and the genome. As 95%
ofhuman breast cancer is not due to inher-
ited mutations, the question becomes one
ofwhat causes people who have inherited a
healthy array of genes to acquire the dis-
ease. It appears likely that a wide variety of
xenobiotic compounds may alter bioactive
estrogen, androgen, or progesterone in
breast cancer cases, in part via Cyp450-
mediated enzymatic reactions. Persons who
have inherited genetic susceptibility to
breast cancer might be especially sensitive
to the proliferative effects ofsome xenohor-
mones from the environment. Persons with
these defects who do not develop the dis-
ease mayhave had greater exposure to bene-
ficial xenohormones or to other protective
factors. Both genetic and hormonal path-
ways that act in a bifunctional manner may
induce aberrant proliferation leading to the
development ofbreast cancer. Some xeno-
estrogens affect the production and
metabolism ofestradiol and thereby regu-
late cumulative levels of the bioavailable
hormone. Some xenohormones directly
modify DNA structure or function.
Structural damage can result from geno-
toxic E2 metabolites and from redox cycling
ofharmful xenoestrogens or other agents
that may produce reactive oxygen species.
Functional damage can include altered
transcriptional activities related to onco-
genes and tumor-suppressor genes, which
are responsible for positive and negative
regulation ofgrowth. Phosphorylation of
p53 gene product or of PI-3-kinase is also
indicative offunctional DNA damage that
impedes cell repair by hindering recogni-
tion of damaged cells and allowing the
accumulation ofharmful mutations. The
growth advantage ofaberrant cells, possibly
by activation ofgenes involved in cell-cycle
progression, leads to the development of
breast cancer (3,4,13,19,33).
The bifunctional genetic-hormonal
hypothesis for breast cancer also provides a
means by which to link the interactive
influence ofdietary factors on disease pro-
gression. The effect ofdietary fat on breast
cancer still remains equivocal. The type of
dietary fat and the levels ofxenoestrogenic
contaminants in the diet may provide
important leads to resolve the observed
inconsistencies. Furthermore, such an
analysis should also provide mechanism-
based interpretation for experimental and
clinical evidence about the role ofdietary
fat in breast cancer development. Poly-
unsaturated fatty acids are considered to
modulate breast carcinogenesis in part by
interfering with membrane-mediated gap-
junctional intercellular communication
(41). This process is critical for cellular
homeostasis whose impairment may pro-
mote growth advantage ofthe cancer cell.
Lipophilic organochlorine pesticides operat-
ing via synergistic interactions inhibit gap-
junctional communication in human
mammary epithelial cells derived from
reduction mammoplasty (42). Xenobiotics
such as the food colorant Red Dye No. 3
have been reported to stimulate cell-cycle
progression in human mammary carcinoma
T47D cells acting via the cyclin-dependent
kinase 2 and ER binding (14,15). Xeno-
biotics that have a carboxylic acid function
can be incorporated structurally into com-
plex lipids such as triglyceride (fat) and
phospholipids (membranes). When mobi-
lized some ofthese metabolites may serve as
signaling molecules similar to phorbol
esters, which are well-established tumor
promoters (41,43). We need to determine
whether bioaccumulated lipophilic xeno-
hormones, xenobiotics such as aromatic
hydrocarbons, and organochlorines are
elevated in women at risk for breast cancer.
This genetic-hormonal hypothesis also
may account for one of the discrepancies
in cancer patterns that was first noted by
the distinguished Danish researcher
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J. Clemmensen (44). Commonly referred
to as Clemmensen's hook, this discrepancy
occurs in the relationship between age and
breast cancer incidence noted for several
countries. Incidence of breast cancer rises
progressively with age up to about 45 years
of age, after which the rate of increase
forms a hook and levels offor declines for
about 10 years and then resumes an
increasing, but more modest, slope. The
ages of this plateau correspond to the
period ofperimenopause, when the ovaries
begin to produce less estrogen and prog-
estin (44). It is tempting to speculate that
the renewed surge in breast cancer after
menopause, especially in obese women,
might be linkedwithxenoestrogens andwith
the production ofendogenous estrogens that
would be greatest in those with proportion-
ally more body fat. Also, obese women
would have higher rates ofmembrane lipid
damage (9-11,23,35,42,45).
With respect to breast cancer, most of
the confirmed risk factors, which relate to
reproductive behavior and dietary factors,
are not easily changed by social policy.
Many of the proposed interventions to
reduce breast cancer involve the lifelong
use of pharmaceutical agents to change
hormonal metabolism or the advocacy of
radical changes in diet, lifestyle, or even
reproductive behavior. As for the latter
point, a generation ofwomen that has
struggled long for reproductive freedom is
unlikely to accept constraints on their
reproductive choices.
This hypothesis has major implications
for breast cancer screening, prevention,
treatment, and management. Biologic
markers ofstructural and functional dam-
age to DNA and ofestradiol metabolism
could prove useful for identifying persons
at risk ofdeveloping breast cancer, assist in
prognostic predictions, and provide base-
lines to assess the efficacy ofpotential ther-
apeutic and nutritional interventions for
prevention, treatment, and management of
the disease.
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